Your browser doesn't support javascript.
loading
Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis.
Trivieri, Maria Giovanna; Robson, Philip M; Vergani, Vittoria; LaRocca, Gina; Romero-Daza, Angelica M; Abgral, Ronan; Devesa, Ana; Azoulay, Levi-Dan; Karakatsanis, Nicolas A; Parikh, Aditya; Panagiota, Christia; Palmisano, Anna; DePalo, Louis; Chang, Helena L; Rothstein, Joseph H; Fayad, Rima A; Miller, Marc A; Fuster, Valentin; Narula, Jagat; Dweck, Marc R; Morgenthau, Adam; Jacobi, Adam; Padilla, Maria; Kovacic, Jason C; Fayad, Zahi A.
Affiliation
  • Trivieri MG; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: Mariagiovanna.trivieri@mountsinai.org.
  • Robson PM; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Vergani V; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • LaRocca G; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Romero-Daza AM; Department of Cardiology, Hospital La Luz-Quirón Salud, Madrid, Spain.
  • Abgral R; Department of Nuclear Medicine, University Hospital of Brest, European University of Brittany, Brest, France.
  • Devesa A; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Azoulay LD; Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale (LIB), Paris, France.
  • Karakatsanis NA; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Division of Radiopharmaceutical Sciences, Department of Radiology, Weill Cornell Medical College, New York, New York, USA.
  • Parikh A; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Panagiota C; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Palmisano A; Experimental Imaging Center, Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • DePalo L; Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Chang HL; International Center for Health Outcomes and Innovation Research, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Rothstein JH; International Center for Health Outcomes and Innovation Research, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Fayad RA; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Miller MA; Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Fuster V; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Narula J; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Dweck MR; British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, UK.
  • Morgenthau A; Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Jacobi A; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Padilla M; Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Kovacic JC; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Victor Chang Cardiac Research Institute and St Vincent's Clinical School, University of NSW, Darlinghurst, New South Wales, Australia.
  • Fayad ZA; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
JACC Cardiovasc Imaging ; 17(4): 411-424, 2024 Apr.
Article de En | MEDLINE | ID: mdl-38300202
ABSTRACT

BACKGROUND:

Imaging with late gadolinium enhancement (LGE) magnetic resonance (MR) and 18F-fluorodeoxyglucose (18F-FDG) PET allows complementary assessment of myocardial injury and disease activity and has shown promise for improved characterization of active cardiac sarcoidosis (CS) based on the combined positive imaging outcome, MR(+)PET(+).

OBJECTIVES:

This study aims to evaluate qualitative and quantitative assessments of hybrid MR/PET imaging in CS and to evaluate its association with cardiac-related outcomes.

METHODS:

A total of 148 patients with suspected CS underwent hybrid MR/PET imaging. Patients were classified based on the presence/absence of LGE (MR+/MR-), presence/absence of 18F-FDG (PET+/PET-), and pattern of 18F-FDG uptake (focal/diffuse) into the following categories MR(+)PET(+)FOCAL, MR(+)PET(+)DIFFUSE, MR(+)PET(-), MR(-)PET(+)FOCAL, MR(-)PET(+)DIFFUSE, MR(-)PET(-). Further analysis classified MR positivity based on %LGE exceeding 5.7% as MR(+/-)5.7%. Quantitative values of standard uptake value, target-to-background ratio, target-to-normal-myocardium ratio (TNMRmax), and T2 were measured. The primary clinical endpoint was met by the occurrence of cardiac arrest, ventricular tachycardia, or secondary prevention implantable cardioverter-defibrillator (ICD) before the end of the study. The secondary endpoint was met by any of the primary endpoint criteria plus heart failure or heart block. MR/PET imaging results were compared between those meeting or not meeting the clinical endpoints.

RESULTS:

Patients designated MR(+)5.7%PET(+)FOCAL had increased odds of meeting the primary clinical endpoint compared to those with all other imaging classifications (unadjusted OR 9.2 [95% CI 3.0-28.7]; P = 0.0001), which was higher than the odds based on MR or PET alone. TNMRmax achieved an area under the receiver-operating characteristic curve of 0.90 for separating MR(+)PET(+)FOCAL from non-MR(+)PET(+)FOCAL, and 0.77 for separating those reaching the clinical endpoint from those not reaching the clinical endpoint.

CONCLUSIONS:

Hybrid MR/PET image-based classification of CS was statistically associated with clinical outcomes in CS. TNMRmax had modest sensitivity and specificity for quantifying the imaging-based classification MR(+)PET(+)FOCAL and was associated with outcomes. Use of combined MR and PET image-based classification may have use in prognostication and treatment management in CS.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sarcoïdose / Cardiomyopathies / Myocardite Type d'étude: Prognostic_studies / Qualitative_research / Risk_factors_studies Limites: Humans Langue: En Journal: JACC Cardiovasc Imaging Sujet du journal: ANGIOLOGIA / CARDIOLOGIA / DIAGNOSTICO POR IMAGEM Année: 2024 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sarcoïdose / Cardiomyopathies / Myocardite Type d'étude: Prognostic_studies / Qualitative_research / Risk_factors_studies Limites: Humans Langue: En Journal: JACC Cardiovasc Imaging Sujet du journal: ANGIOLOGIA / CARDIOLOGIA / DIAGNOSTICO POR IMAGEM Année: 2024 Type de document: Article